ArticleESMO real world data and digital oncology2026
Real-world outcomes in patients with advanced epithelial ovarian cancer receiving niraparib as first-line maintenance: a European retrospective cohort study.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In this real-world study, outcomes were evaluated in patients with stage III advanced epithelial ovarian cancer (EOC) with no visible residual disease (NVRD) after primary cytoreductive surgery (PCS), a subgroup excluded from the phase III PRIMA trial. Materials and methods: The noninterventional, retrospective EUROPA study included patients with advanced (stage III or IV) EOC who initiated first-line maintenance (1LM) niraparib monotherapy (index date) between 1 October 2018 and 31 March 2023 in France, Germany, and Italy. Real-world time to treatment discontinuation (rwTTD) and real-world progression-free survival (rwPFS) were assessed among all patients and in a subgroup of patients with stage III disease and NVRD after PCS (stage III NVRD subgroup). Results: Among 186 patients in this study, 48 were included in the stage III NVRD subgroup. Median (95% CI) rwTTD in the overall cohort versus stage III NVRD subgroup was 10.6 (7.8-18.6) versus 26.2 (8.9-not reached) months. In the overall cohort, median (95% CI) rwPFS was 14.7 (10.1-29.3) months but not reached in the stage III NVRD subgroup. rwTTD and rwPFS probabilities were higher for the stage III NVRD subgroup versus overall cohort at 12, 24, and 36 months after index date. Conclusions: In the real-world setting, patients with stage III advanced EOC and NVRD after PCS had descriptively better clinical outcomes than those in the overall cohort with advanced EOC. The use of 1LM niraparib in these patients, a subgroup excluded from the PRIMA trial, appeared to be associated with clinically meaningful real-world outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.